News | Coronavirus (COVID-19) | May 31, 2023

People Coinfected with SARS-CoV-2 and Cytomegalovirus are at Increased Risk of Developing Cardiovascular Disease

Cytomegalovirus (CMV) is one of the most prevalent herpesviruses worldwide.

The researcher Alejandra Pera, in her office. Image courtesy of University of Córdoba. 

May 31, 2023 — Cytomegalovirus (CMV) is one of the most prevalent herpesviruses worldwide. Depending on the geographical area, it can affect between 40% and 90% of the population and, although it does not produce symptoms in healthy people, the control of this chronic infection requires constant work by the immune system, which is constantly fighting to keep it at bay. A study by the University of Cordoba (UCO) and Cordoba’s Maimonides Biomedical Research Institute (IMIBIC) evaluated the effect of SARS-CoV-2 coronavirus infection in patients who had mild or asymptomatic COVID-19, and who were also infected with cytomegalovirus. According to the results of this study, people coinfected with both pathogens present the premature aging of their immune systems, which is related to a greater risk of suffering cardiovascular disease at an earlier age. 

As the principal investigator on the study, Dr. Alejandra Pera, explains, this does not mean that people who have been infected with these two viruses will necessarily develop cardiovascular problems. However, given the prevalence of both viruses, it does represent one more circumstance "that should be taken into account in the patient's clinical history" and added to the list of other risk factors, such as alcohol and tobacco consumption, the regular intake of foods high in saturated fats, and a sedentary lifestyle.  


T-cells, in the Right Measure 

The study analyzed the state of the immune systems of people with and without chronic cytomegalovirus infection 3 and 12 months after mild or asymptomatic infection by SARS-CoV-2 (the coronavirus responsible for COVID-19). According to the results, in patients infected by both viruses, an expansion of T-cells with increased functionality is generated. These T cells are memory-endowed lymphocytes that are essential for our body's defense, but when their functions are excessively activated, they generate inflammation and can damage the vascular endothelium, a layer of cells that lines the inside of blood vessels. "Cytomegalovirus alone causes these cells to increase. Now we have found that SARS-CoV-2 has an added effect," the researcher adds.  

One of the most striking aspects of the study is that this effect was documented in people who were infected with even mild or asymptomatic forms of the coronavirus. The scientific community is studying the effects to a greater extent in patients with severe symptoms, "but we are seeing that COVID-19 also has medium- and long-term consequences in people who had the disease without complications, and that we should take this into account", emphasized the study's lead author. 

Vaccines as Prevention 

The study, whose first author is UCO predoctoral researcher Pablo Álvarez, showed that after infection with SARS-CoV-2 there is an increase in cells associated with cardiovascular disease in patients previously infected with cytomegalovirus. In those individuals who became ill with COVID after having been vaccinated, however, this phenomenon does not occur. 
Although Dr. Pera stressed that further studies should be conducted to take into account the effect of the different waves and variants of the coronavirus, the results seem to indicate that the vaccines prevent and mitigate this uncontrolled expansion of T cells capable of doing cardiovascular damage.  

For more information: 


Related COVID-19 Content: 

FDA Clears Third COVID-19 Vaccine From Janssen 

FDA Clears First COVID-19 Vaccine Under an Emergency Use Authorization 

FDA Approved Second COVID-19 Vaccine From Moderna 

Cardiologists Should Prioritize Influenza Vaccination Amidst COVID-19 Pandemic 

Who Qualifies for the COVID Vaccine Under CDC Guidelines 

Cardiology related COVID news and video 

FDA Clears First COVID-19 Vaccine Under an Emergency Use Authorization 

VIDEO: Lingering Myocardial Involvement After COVID-19 Infection — Interview with Aaron Baggish, M.D. 

COVID-19 Can Impact Hearts in Young Children 

COVID-19 Positive STEMI Patients Have Higher Mortality  

VIDEO: ECMO Hemodynamic Support Effective in Sickest COVID-19 Patients — Interview with Ryan Barbaro, M.D. 

The Cardiovascular Impact of COVID-19 

COVID-19 Cardiovascular Registry Details Disparities Among Hospitalized Patients 

VIDEO: How to Reduce COVID Exposure, Speed Exams and Cut Readmissions in Cardiology Departments— Interview with Keith Ellis, M.D., 

COVID-19 Patients With Cardiovascular Disease Have In-hospital Mortality Rates of 25 to 38 Percent 

Kawasaki-like Inflammatory Disease Affects Children With COVID-19 

VIDEO: What Are The Long-term Cardiac Impacts of COVID-19 Infection — Interview with Todd Hurst, M.D. 

VIDEO: Overview of Multisystem Inflammatory Syndrome in Children (MIS-C) in COVID-19 Exposed Children 

Case Study Describes One of the First U.S. Cases of MIS-C 

Find more cardiology related COVID content 

Related Content

News | Cardiovascular Clinical Studies

February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart ...

Home February 21, 2024
News | Cardiovascular Clinical Studies

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

Home February 15, 2024
News | Cardiovascular Clinical Studies

January 3, 2024 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce the completion of ...

Home January 03, 2024
News | Cardiovascular Clinical Studies

December 19, 2023 — Peerbridge Health has announce the successful completion and findings of its prospective ...

Home December 19, 2023
News | Cardiovascular Clinical Studies

December 14, 2023 — Published results of a large, national heart attack study show that patients with a life-threatening ...

Home December 14, 2023
News | Cardiovascular Clinical Studies

December 11, 2023 — A world without cardiovascular disease (CVD) is possible, yet millions of lives are lost prematurely ...

Home December 11, 2023
News | Cardiovascular Clinical Studies

December 8, 2023 — Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac ...

Home December 08, 2023
News | Cardiovascular Clinical Studies

November 29, 2023 — Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

Home November 29, 2023
Subscribe Now